Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Type I IFNs Control Antigen Retention and Survival of CD8a Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently in response to a growing tumor. However, the innate immune mechanisms that promote natural antitumor T cell responses are undefined. In human metastatic melanoma, there was a correlation between a type I interferon (IFN) transcriptional profile and T cell markers in metastatic tumor tissue. In mice, IFN-β...

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.

Successful chemotherapy accounts for both tumor-related factors and host immune response. Compelling evidence suggests that some chemotherapeutic agents can induce an immunogenic type of cell death stimulating tumor-specific immunity. Here, we show that cyclophosphamide (CTX) exerts two types of actions relevant for the induction of antitumor immunity in vivo: (i) effect on dendritic cell (DC) ...

Cross-Presentation of Cell-Associated Antigens by Mouse Splenic Dendritic Cell Populations

Cross-presentation of cell-associated antigens (Ag) plays an important role in the induction of anti-tumor responses, autoimmune diseases, and transplant rejection. While several dendritic cell (DC) populations can induce pro-inflammatory CD8(+) T cell responses to cell-associated Ag during infection, in the absence of infection, cross-priming of naïve CD8(+) T cells is highly restricted. Compa...

Uptake of Autologous and Allogenic Tumor Cell Antigens by Dendritic Cells

Background: Dendritic cells (DCs) are professional antigen presenting cells (APCs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy.  Previous studies indirectly demonstrated that DCs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (TAA) which elicits anti-tumor immune respo...